U.S. General Merchandise and Department Stores Stock News

Abbott Laboratories (ABT) is back in focus after second quarter 2026 earnings topped market expectations, powered by Medical Devices and Diagnostics, and a higher full year adjusted EPS outlook lifted the stock sharply. See our latest analysis for Abbott Laboratories. The latest results have triggered a sharp 1 day share price return of 10.71% and lifted Abbott Laboratories to US$98.83, yet the year to date share price return is still down 20.42% and the 1 year total shareholder return is...

Deere (DE) is back in focus after agreeing with the Federal Trade Commission and five states to broaden farmers' access to equipment repair tools, closing a regulatory matter and clarifying its approach to equipment maintenance. See our latest analysis for Deere. At a share price of $598.97, Deere has delivered a 28.31% year to date share price return, alongside a 21.50% total shareholder return over 1 year and 82.07% over 5 years. This suggests momentum has been building around the stock...

In recent commentary, HNI’s 9.3% annual earnings per share growth trailing revenue, absence of free cash flow, and net-debt-to-EBITDA of 6x have raised concerns about its ability to reinvest or return capital to shareholders. This combination of limited cash generation, elevated leverage, and a relatively low forward valuation is prompting investors to reassess the company’s overall risk profile and financial flexibility. We’ll now examine how concerns about HNI’s high net-debt-to-EBITDA...

CVS Health stock has delivered a strong 74.4% return over the past year, yet its valuation checks lean expensive and suggest the current share price may already be pricing in a lot of good news. A 74.4% one year gain can signal renewed confidence in CVS Health, but it also raises the bar for what future performance needs to justify the current price. Regulatory settlements around insulin pricing and Omnicare, along with ongoing legal and compliance obligations, may affect how investors...

Teladoc Health (TDOC) is back in focus after fresh analyst commentary highlighted concerns around flat sales, falling revenue per user, and a business model geared more toward user growth than monetization, as the next earnings date approaches. See our latest analysis for Teladoc Health. Against this cautious backdrop, Teladoc Health’s share price has climbed to $9.47, with a 30 day share price return of 25.10% and a 90 day gain of 66.43%, while the 3 year total shareholder return is down...

Sprouts Farmers Market (SFM) is drawing fresh attention after giving LivReal, a fruit flavored energy drink made from real squeezed fruit, nationwide placement in its Innovation Set program, supported by extensive in store marketing. See our latest analysis for Sprouts Farmers Market. Despite the LivReal rollout and other recent product initiatives, Sprouts Farmers Market’s share price has eased, with a 7 day share price return of 8.35% and a 30 day share price return of 11.89%. The 1 year...

Earlier this week, DaVita highlighted that it is heading into its Q2 FY2026 earnings report with stronger treatment volumes and productivity gains, leading management to raise adjusted operating income and EPS guidance. This combination of improving operational metrics and higher guidance suggests investors are watching closely how sustained efficiency improvements could influence DaVita’s longer-term earnings profile. Next, we’ll explore how DaVita’s upgraded adjusted operating income and...

In the past few days, MP Materials reported Q1 2026 results showing year-over-year revenue growth and better-than-expected adjusted earnings, while confirming strong liquidity to fund its capital-intensive rare earth and magnet projects. The company’s continued pivot from rare earth concentrate sales to higher-value domestic magnet production, supported by U.S. government agreements, is steadily reshaping its role in the critical materials supply chain. We’ll now examine how MP Materials’...

Founder led companies can appeal when inflation, interest rates and growth signals are pulling in different directions, because leadership is often financially and reputationally tied to long term outcomes. With central banks adjusting policy, bond yields shifting and trade and energy trends in focus, many investors are looking for businesses where decision makers have real skin in the game. This Founder Led Companies screener aims to surface stocks where leadership is closely aligned with...

Amneal Pharmaceuticals (AMRX) is back in focus after a recent review highlighted strong long term shareholder returns, alongside slower projected revenue growth, stagnant free cash flow margins, and mixed outcomes from past growth initiatives. See our latest analysis for Amneal Pharmaceuticals. At a share price of $18.04, Amneal Pharmaceuticals has seen strong short term momentum, with a 30 day share price return of 11.02% and year to date share price return of 42.50%, on top of a 1 year...

With inflation trends mixed, bond yields moving in different directions across regions, and energy prices influenced by supply tensions, investors are paying closer attention to what really underpins a stock: its cash generation. The Undervalued Stocks Based On Cash Flows screener focuses on companies where discounted cash flow estimates from SWS suggest the share price does not fully reflect their cash flow potential. For readers looking for ideas grounded in fundamentals rather than...

Why POET Technologies Is Back on Retail Investors' Radar A sharp single day move of more than 10% in POET Technologies (NasdaqCM:POET) has pulled the stock back into focus, as retail sentiment turns bullish and institutional commentary grows louder. Recent coverage highlights three forces now intersecting around POET Technologies. Retail investors have shifted from a bearish stance to a more optimistic tone, some Wall Street analysts are paying closer attention, and Photon Capital is publicly...

Madrigal Pharmaceuticals (MDGL) has set July 30, 2026 as the date for its second quarter 2026 earnings release, with management hosting a webcast before the U.S. market opens to discuss the results. See our latest analysis for Madrigal Pharmaceuticals. At a share price of $545.53, Madrigal Pharmaceuticals has seen short term share price momentum cool slightly, although its 30 day share price return of 8.85% sits alongside a 1 year total shareholder return of 56.43% and a 5 year total...

Venture Global stock has surged about 80.0% year to date, yet the valuation checks still lean cheap. This sets up a clear question over whether recent enthusiasm around its LNG growth story is matched by a margin of safety in the current price. The roughly 80.0% gain year to date means investors are now paying a much higher price to access the same cash flow potential than they were at the start of 2026. Fresh long term LNG supply contracts and new funding for shipping capacity can support...

Coca-Cola's fairlife dairy subsidiary has been hit by a ransomware attack. The incident has led to a temporary suspension of all U.S. production operations at fairlife. The disruption raises fresh questions about cybersecurity resilience at large consumer brands. Coca-Cola (NYSE:KO) is facing an operational setback after the cybersecurity breach at fairlife, a key dairy subsidiary. With Coca-Cola shares recently at $84.92 and the stock up 2.8% over the past week, 5.8% over the past month,...

Fresh analyst commentary around Chubb (CB) centers on projections for its upcoming earnings report, where Wall Street expects year over year growth in both EPS and revenue, with some attention on potential outperformance versus consensus. See our latest analysis for Chubb. Chubb’s recent 1 month share price return of 4.5% and 1 year total shareholder return of 26.36% suggest momentum has been building, supported by a 3 year total shareholder return of 79.47% and a 5 year total shareholder...

Glaukos (GKOS) has drawn fresh investor attention after its stock closed at $155.39, capping a strong run over the past month and past 3 months without a single defining headline driving the move. See our latest analysis for Glaukos. Glaukos has seen momentum build, with a 30 day share price return of 21.85% and a year to date share price return of 40.34%, alongside a 1 year total shareholder return of 56.96% and 5 year total shareholder return of 210.78%. If Glaukos's recent run has you...

Kaiser Aluminum stock has delivered a 127.7% total return over the past three years, yet current valuation checks suggest it no longer looks like an obvious bargain. The Discounted Cash Flow (DCF) intrinsic value estimate points to a price that is roughly in line with where the shares trade today. After such a strong run, the core question for investors is whether recent growth expectations and operational progress are already well reflected in the current price. The 127.7% return over three...

Global convenience store chains are back in focus after Seven & i’s interest in Poland’s Zabka Group pushed both companies’ shares higher and reminded investors how powerful store expansion and acquisitions can be for growth plans. When a retailer looks to add thousands of locations across new regions, it can reshape the outlook for competitors, suppliers, and landlords as well. This article looks at 3 stocks exposed to the same news theme, all flagged by a Global Convenience Store Expansion...

Ambiq Micro (NYSE:AMBQ) has completed an upsized public equity offering, including the full exercise of the underwriters' overallotment option. The transaction brings in additional capital to the company, expanding its financial resources beyond the initial deal size. This capital raise represents a fresh development for shareholders, with potential implications for Ambiq Micro's growth plans and balance sheet flexibility. Ambiq Micro enters this new phase of funding with shares last...

In recent days, Frontline has drawn increased market attention as heightened trading and options activity coincided with new developments in its global shipping operations, boosting its visibility across the NYSE Composite. This renewed focus on Frontline’s role in worldwide tanker shipping underscores how shifts in seaborne trade patterns can quickly reframe investor interest in the company’s core business. Building on this heightened trading and options activity, we’ll now examine how...

With US 10 year Treasury yields easing to 4.56% after softer inflation data and rising oil prices keeping inflation concerns alive, dividend stocks can look appealing as potential income anchors while markets reassess the interest rate path. This article focuses on dividend paying companies that may be more sensitive to changes in inflation expectations and Fed policy, and are screened for at least a 1% yield and manageable payout ratios. You will see three dividend stocks that appear...

Tapestry stock is coming off a striking run over the past five years, yet its valuation checks now point to a company that no longer looks obviously cheap, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model sitting close to the current share price while traditional multiples lean expensive. Tapestry has delivered a 311.2% return over 5 years, which means anyone holding through that period has already seen a very large amount of value recognized by the market. Future...

First Horizon (FHN) opened Q2 2026 with total revenue of US$871 million and basic EPS of US$0.55, alongside trailing 12 month net income of US$1.03 billion and EPS of about US$2.11. Over recent quarters the company has seen revenue move from US$800 million in Q2 2025 to US$894 million in Q3 2025, US$888 million in Q4 2025, US$847 million in Q1 2026 and now US$871 million. Over the same period, quarterly basic EPS stepped from US$0.46 to US$0.50, US$0.52, US$0.54 and US$0.55. With net margin...